過敏性腸症候群の分類システムの安定性
Mais Khasawneh1,2, Vivek C Goodoory1,2, Cho Ee Ng3
1Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.
Alimentary pharmacology & therapeutics
|December 25, 2025
まとめ
過敏性腸症候群(IBS)の分類の安定性は様々である。便の形態と心理的負担の分類は12ヶ月で最も安定していたが、単一の方法ではIBS症状の変動を完全に捉えることはできなかった。
科学分野:
- 消化器病学
- 精神医学
- 臨床研究
背景:
- 過敏性腸症候群(IBS)は、一般的な機能性消化管障害である。
- 現在のIBS分類は便の形態に依存しているが、症状のパターンは動的である。
- この変動は、効果的なサブタイプベースの管理に課題をもたらす。
研究 の 目的:
- 4つの異なる過敏性腸症候群(IBS)分類方法の12ヶ月の安定性を評価すること。
- 便の形態、最も厄介な症状、および2つの潜在クラス分析(LCA)モデルを使用して安定性を評価すること。
- 消化器症状および心理的症状を含む包括的なLCA、および心理的負担に基づく単純化されたLCAを調査すること。
主な方法:
- 英国のレジストリからIBSのRome IV基準を満たす参加者を募集した。
- ベースライン時および12ヶ月時に消化器症状および心理的症状を評価する検証済みのオンラインアンケートを実施した。
- Cohenのkappa統計量を使用して分類の安定性を評価した。
主要な成果:
- 便の形態に基づくサブタイピングは最も高い安定性(κ=0.60)を示し、下痢優位のIBS症例の83%が安定していた。
- 心理的負担に基づく分類も中程度の安定性(κ=0.54)を示した。
- 潜在クラス分析(LCA)法、特に7クラスモデル(κ=0.37)は、12ヶ月の期間で安定性が低かった。
結論:
- 既存のIBS分類システムは、12ヶ月で中程度の安定性しか示さず、疾患固有の変動性を反映している。
- 便の形態と心理的負担が、最も安定した分類パラメータであると思われる。
- 今後の研究では、IBS管理の改善のために、消化器および心理的要因の両方を統合する動的モデルに焦点を当てるべきである。
さらに関連する動画
関連する概念動画
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
703
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
703
Irritable Bowel Syndrome I: Introduction
879
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
879
Chronic Bowel Disorders: Introduction
721
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
721
Irritable Bowel Syndrome III: Medical and Nursing Management
608
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
608
Drugs for Treatment of Diarrhea-Predominant IBS
590
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
590
Drugs for Treatment of Constipation-Predominant IBS
664
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
664


